Michael's main focus areas are the planning, development, implementation and evaluation of benefit-risk management solutions, as well as the optimization of processes around benefit-risk management. He is engaged in developing and applying (benefit-) risk analysis and signal management methodologies in order to make RM planning more formally reproducible. Furthermore, he supports the development, implementation and evaluation of effectiveness of additional risk minimization and PV measures in the context of RMPs, as well as post-authorization studies to optimize the benefit-risk profiles of medicines.

Steve Mayall is a Principal Consultant in Huron’s Life Sciences Practice (formerly known as Pope Woodhead). He has advised a wide variety of global pharmaceutical and biotech companies on benefit-risk management for more than 15 years. Key areas have included developing risk management plans; designing, implementing and evaluating risk minimisation and pharmacovigilance activities; and performing structured benefit-risk assessments.